logo

For the Inventor, By the Inventor

Dallas, TX, United States of America

Ellen S Vitetta

This inventor holds 18 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Immunotherapy Research. Top assignees: The University of Texas System, Board of Regents, Nanoco, LLC. Active years: 1987-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ellen S Vitetta. Retrieved from https://idiyas.com/inventor/ellen-s-vitetta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 61.1


Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 508(Granted Patents)


Company Filing History:

goldMedal15 out of 5,644 
 
The University of Texas System
 patents
silverMedal1 out of 11 
 
Board of Regents
 patents
bronzeMedal1 out of 1 
 
Nanoco, LLC
 patent
4. 1 out of 14 
 
Wilk Patent Development Corporation
 patents

Years Active: 1987-2017

Loading Chart...
Loading Chart...
Areas of Expertise:
Peptoid Vaccines
Antibody Homoconjugates
Immunotoxins
Tumor Cell Growth Arrest
Aerosolized Ricin
Nanostructures
Proteinaceous Compounds
Monoclonal Antibodies
Toxin Conjugates
Cell Cycle Arrest
Therapeutic Compositions
18 patents (USPTO):Explore Patents
1. 9770504 - Generating peptoid vaccines (2017-09-26),
2. 8658168 - Compositions and methods for homoconjugates of antibodies which induce growth arrest of apoptosis of tumor cells (2014-02-25),
3. 8323665 - Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin (2012-12-04),
4. 7829668 - Compositions and methods for modifying toxic effects of proteinaceous compounds (2010-11-09),
5. 7668603 - Medical composition employing nanostructures (2010-02-23),
6. 7452971 - Compositions and methods for modifying toxic effects of proteinaceous compounds (2008-11-18),
7. 7175848 - Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin (2007-02-13),
8. 7133725 - Method and related composition employing nanostructures (2006-11-07),
9. 6960652 - Compositions and methods for modifying toxic effects of proteinaceous compounds (2005-11-01),
10. 6566500 - Compositions and methods for modifying toxic effects of proteinaceous compounds (2003-05-20),
11. 6368596 - Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells (2002-04-09),
12. 5767072 - Therapeutic compositions comprising a CD4 peptide and methods of (1998-06-16),
13. 5686072 - Epitope-specific monoclonal antibodies and immunotoxins and uses thereof (1997-11-11),
14. 5612185 - Method for identifying tumor cells in cell cycle arrest (1997-03-18),
15. 5578706 - Methods and compositions concerning homogenous immunotoxin preparations (1996-11-26),

Title: The Innovative Journey of Ellen S. Vitetta

Introduction: Ellen S. Vitetta, a pioneering inventor hailing from Dallas, TX, has made significant contributions to the field of biomedicine through her groundbreaking innovations.

Latest Patents: Ellen S. Vitetta holds several patents in the field of immunology and cancer research, focusing on novel treatment methods and drug delivery systems.

Career Highlights: Throughout her illustrious career, Ellen S. Vitetta has been recognized for her exceptional work in developing targeted therapies for various diseases, particularly cancer. Her research has paved the way for more effective and personalized treatment options.

Collaborations: Ellen S. Vitetta has collaborated with leading researchers, pharmaceutical companies, and academic institutions worldwide to further advance the field of biomedicine. Her collaborative efforts have resulted in innovative solutions with far-reaching impacts.

Conclusion: Ellen S. Vitetta's dedication to innovation and her relentless pursuit of scientific excellence continue to inspire future generations of inventors and researchers in the quest for improved healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…